


PHARMACEUTICAL 2022

Zoetis Inc. Rank 273 of 466









PHARMACEUTICAL 2022

Zoetis Inc. Rank 273 of 466



The relative strengths and weaknesses of Zoetis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zoetis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Zoetis Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is 85%, being 6.6% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	6,930,000
Cost of Goods Sold	2,303,000
Intangible Assets	4,156,000
Liabilities, Current	1,797,000
Liabilities, Non-Current	6,982,000
Other Assets	392,000
Other Compr. Net Income	-31,000
Other Expenses	882,000
Other Liabilities	577,000
Other Net Income	-48,000
Other Revenues	7,776,000
Property and Equipment	2,422,000
Research and Development	508,000
Selling, General and Administrative Expense	2,001,000

Output Variable	Value in 1000 USD
Assets	13,900,000
Liabilities	9,356,000
Expenses	5,694,000
Revenues	7,776,000
Stockholders Equity	4,544,000
Net Income	2,034,000
Comprehensive Net Income	2,018,500
Economic Capital Ratio	85%

